- Home
- BHAT vs KZIA Comparison
BHAT vs KZIA Comparison
Compare BHAT & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BHAT | KZIA |
|---|---|---|
| Founded | 2010 | 1994 |
| Country | China | Australia |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.1M | 161.5M |
| IPO Year | 2019 | 1999 |
Fundamental Metrics
Financial Performance| Metric | BHAT | KZIA |
|---|---|---|
| Price | $1.15 | $6.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $17.67 |
| AVG Volume (30 Days) | 89.5K | ★ 257.9K |
| Earning Date | 05-12-2026 | 12-26-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $18,972,415.00 | $1,199,108.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.07 | $2.86 |
| 52 Week High | $24.50 | $17.40 |
Technical Indicators
Market Signals| Indicator | BHAT | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 34.65 | 37.94 |
| Support Level | $1.11 | $6.05 |
| Resistance Level | $1.39 | $11.06 |
| Average True Range (ATR) | 0.12 | 1.63 |
| MACD | -0.02 | -0.67 |
| Stochastic Oscillator | 8.16 | 5.61 |
Price Performance
Historical ComparisonAbout BHAT Blue Hat Interactive Entertainment Technology
Blue Hat Interactive Entertainment Technology is focused on commodity trading, including chemicals, jewelry, and precious metals such as gold. It operates a gold and diamond trading and supply chain business. Its business model encompasses physical gold trading, diamond trading, gold derivatives trading, and the development of AI-enabled trading platforms. Its segments include Diamond trading, Commodity trading, Information service, Interactive toys - animation series, and Interactive toys - game series. It derives revenue from Diamond trading. The majority of its revenues are generated in PRC.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.